India's Jodas Expoim experiencing problems with construction of pharma factory in Russia

Indian pharmaceutical company Jodas Expoim is experiencing serious problems with the construction of its first enterprise in the Russian Federation, to be located in the city of Moscow, due to serious delays in approving the project by the Moscow city government and other Russian regulators, reports The Pharma Letter’s local correspondent.

An official spokesman of Jodas Expoim’s Russian office said in an interview with Russian Kommersant business paper that at the beginning of 2022 the company completed the acquisition of the Russian enterprise, known as Omni-Service, which owns an unfinished production plant for porcelain products with a total area of 7.500 square meters in the city of Chertanovo in the south of Moscow.

According to Jodas Expoim’s initial plans, the construction of a new plant and a warehouse was supposed to begin at the end of 2022, with the launch of production set to be in 2024. It is expected that the new plant will produce oncological drugs and biosimilars at the enterprise with the output of 500,000 bottles of liquid forms and 11.3 million tablets and capsules per year. However, so far, the construction has not yet started due to bureaucratic and other hurdles.